A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
Public ClinicalTrials.gov record NCT04718103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.
Study identification
- NCT ID
- NCT04718103
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 397 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2021 (Actual)
- Primary completion
- Apr 11, 2024 (Actual)
- Completion
- Apr 11, 2024 (Actual)
- Last update posted
- Nov 29, 2024
2021 – 2024
United States locations
- U.S. sites
- 41
- U.S. states
- 20
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Alabaster | Alabama | 35007 | — |
| GSK Investigational Site | Mobile | Alabama | 36608 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Beverly Hills | California | 90048 | — |
| GSK Investigational Site | Lancaster | California | 93534 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80923 | — |
| GSK Investigational Site | Lafayette | Colorado | 80026 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Hialeah | Florida | 33014 | — |
| GSK Investigational Site | Miami | Florida | 33144 | — |
| GSK Investigational Site | Miami | Florida | 33186 | — |
| GSK Investigational Site | Miami Lakes | Florida | 33014 | — |
| GSK Investigational Site | Orlando | Florida | 32803 | — |
| GSK Investigational Site | Atlanta | Georgia | 30281 | — |
| GSK Investigational Site | Evanston | Illinois | 60026 | — |
| GSK Investigational Site | Columbia | Maryland | 21044 | — |
| GSK Investigational Site | Dearborn | Michigan | 48124 | — |
| GSK Investigational Site | Ypsilanti | Michigan | 48197 | — |
| GSK Investigational Site | St Louis | Missouri | 63110 | — |
| GSK Investigational Site | Northfield | New Jersey | 08225 | — |
| GSK Investigational Site | Toms River | New Jersey | 08755 | — |
| GSK Investigational Site | The Bronx | New York | 10467 | — |
| GSK Investigational Site | Huntersville | North Carolina | 28078 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45229 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45231 | — |
| GSK Investigational Site | Edmond | Oklahoma | 73034 | — |
| GSK Investigational Site | Altoona | Pennsylvania | 16601 | — |
| GSK Investigational Site | DuBois | Pennsylvania | 15801 | — |
| GSK Investigational Site | Hershey | Pennsylvania | 17033 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Rapid City | South Dakota | 57702 | — |
| GSK Investigational Site | Allen | Texas | 75013 | — |
| GSK Investigational Site | Boerne | Texas | 78006 | — |
| GSK Investigational Site | Dallas | Texas | 75225 | — |
| GSK Investigational Site | Houston | Texas | 77084 | — |
| GSK Investigational Site | San Antonio | Texas | 78207 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | San Antonio | Texas | 78258 | — |
| GSK Investigational Site | Bellingham | Washington | 98225 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04718103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 29, 2024 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04718103 live on ClinicalTrials.gov.